Flotation of new US radiotherapy developer imminent
This article was originally published in Clinica
Executive Summary
Photoelectron hopes to go public later this week, giving US investors a chance to buy into the developer of a new radiation cancer treatment device, the Photon Radiosurgery System (PRS). The initial public offering comes barely six weeks after the company submitted its system for 510(k) clearance in the US for the treatment of metastatic brain cancer.